NZ717927A - Compositions for the treatment of hypertension and/or fibrosis - Google Patents
Compositions for the treatment of hypertension and/or fibrosisInfo
- Publication number
- NZ717927A NZ717927A NZ717927A NZ71792714A NZ717927A NZ 717927 A NZ717927 A NZ 717927A NZ 717927 A NZ717927 A NZ 717927A NZ 71792714 A NZ71792714 A NZ 71792714A NZ 717927 A NZ717927 A NZ 717927A
- Authority
- NZ
- New Zealand
- Prior art keywords
- fibrosis
- hypertension
- treatment
- compositions
- prophylactic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2013903573A AU2013903573A0 (en) | 2013-09-17 | Compositions for the treatment of hypertension and/or fibrosis | |
| PCT/AU2014/000923 WO2015039173A1 (en) | 2013-09-17 | 2014-09-17 | Compositions for the treatment of hypertension and/or fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ717927A true NZ717927A (en) | 2018-12-21 |
Family
ID=52687998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ717927A NZ717927A (en) | 2013-09-17 | 2014-09-17 | Compositions for the treatment of hypertension and/or fibrosis |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9458093B2 (OSRAM) |
| EP (1) | EP3046901B1 (OSRAM) |
| JP (1) | JP6122548B2 (OSRAM) |
| KR (1) | KR101736416B1 (OSRAM) |
| CN (1) | CN105683152B (OSRAM) |
| AP (1) | AP2016009079A0 (OSRAM) |
| AU (1) | AU2014324078B2 (OSRAM) |
| BR (1) | BR112016005601B1 (OSRAM) |
| CA (1) | CA2924356C (OSRAM) |
| DK (1) | DK3046901T3 (OSRAM) |
| ES (1) | ES2655455T3 (OSRAM) |
| IL (1) | IL244621A (OSRAM) |
| MX (1) | MX368865B (OSRAM) |
| MY (1) | MY172557A (OSRAM) |
| NO (1) | NO3046901T3 (OSRAM) |
| NZ (1) | NZ717927A (OSRAM) |
| PH (1) | PH12016500497B1 (OSRAM) |
| PL (1) | PL3046901T3 (OSRAM) |
| RU (1) | RU2635564C2 (OSRAM) |
| SG (1) | SG11201601642WA (OSRAM) |
| UA (1) | UA118111C2 (OSRAM) |
| WO (1) | WO2015039173A1 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3284981B2 (ja) | 1998-11-02 | 2002-05-27 | 株式会社デンソー | 車両用交流発電機およびそのステータの製造方法 |
| US9956166B2 (en) | 2013-09-18 | 2018-05-01 | Sorrento Therapeutics, Inc. | Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin |
| DK3271326T3 (da) * | 2015-03-18 | 2021-01-25 | Vectus Biosystems Ltd | Sammensætninger til behandling af nyre- og/eller leversygdom |
| WO2016145479A1 (en) * | 2015-03-18 | 2016-09-22 | Vectus Biosystems Limited | Compositions for the treatment of fibrosis and fibrosis-related conditions |
| ES2861434T3 (es) | 2015-09-22 | 2021-10-06 | Vectus Biosystems Ltd | Síntesis de compuestos terfenilo |
| KR102508022B1 (ko) * | 2016-04-13 | 2023-03-10 | 보드 오브 리젠츠 오브 디 유니버시티 오브 네브라스카 | 레시니페라톡신을 사용한 투여 방법 및 심혈관 질환을 치료하는 방법 |
| EP3490970B1 (en) * | 2016-07-28 | 2023-09-13 | Vectus Biosystems Limited | Compositions for the treatment of pulmonary fibrosis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2694288B1 (fr) * | 1992-06-30 | 1994-09-09 | Rhone Poulenc Agrochimie | Phenylbenzamides fongicides et procédés pour les préparer. |
| BRPI0511367B8 (pt) | 2004-06-11 | 2021-05-25 | Vectus Biosystems Ltd | uso de uma composição,composição, uso de vip e/ou de um fragmento ativo do mesmo |
| AU2006322656B2 (en) * | 2005-12-09 | 2012-03-08 | Vectus Biosystems Limited | VIP fragments and methods of use |
| US20120088737A2 (en) * | 2009-10-02 | 2012-04-12 | Ajinomoto Co., Inc | Novel acyl guanidine derivatives |
| AP2016009080A0 (en) * | 2013-09-17 | 2016-03-31 | Vectus Biosystems Pty Ltd | Compositions for the treatment of hypertension and/or fibrosis |
-
2014
- 2014-09-17 MX MX2016003371A patent/MX368865B/es active IP Right Grant
- 2014-09-17 MY MYPI2016000482A patent/MY172557A/en unknown
- 2014-09-17 CN CN201480050979.1A patent/CN105683152B/zh active Active
- 2014-09-17 KR KR1020167008664A patent/KR101736416B1/ko active Active
- 2014-09-17 BR BR112016005601-9A patent/BR112016005601B1/pt active IP Right Grant
- 2014-09-17 AU AU2014324078A patent/AU2014324078B2/en active Active
- 2014-09-17 NO NO14845373A patent/NO3046901T3/no unknown
- 2014-09-17 ES ES14845373.1T patent/ES2655455T3/es active Active
- 2014-09-17 DK DK14845373.1T patent/DK3046901T3/en active
- 2014-09-17 RU RU2016112257A patent/RU2635564C2/ru active
- 2014-09-17 EP EP14845373.1A patent/EP3046901B1/en active Active
- 2014-09-17 CA CA2924356A patent/CA2924356C/en active Active
- 2014-09-17 WO PCT/AU2014/000923 patent/WO2015039173A1/en not_active Ceased
- 2014-09-17 SG SG11201601642WA patent/SG11201601642WA/en unknown
- 2014-09-17 PL PL14845373T patent/PL3046901T3/pl unknown
- 2014-09-17 US US15/022,278 patent/US9458093B2/en active Active
- 2014-09-17 AP AP2016009079A patent/AP2016009079A0/xx unknown
- 2014-09-17 NZ NZ717927A patent/NZ717927A/en unknown
- 2014-09-17 UA UAA201602267A patent/UA118111C2/uk unknown
- 2014-09-17 JP JP2016515425A patent/JP6122548B2/ja active Active
-
2016
- 2016-03-14 PH PH12016500497A patent/PH12016500497B1/en unknown
- 2016-03-16 IL IL244621A patent/IL244621A/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015010921A (es) | Compuestos de carbazol utiles como inhibidores de bromodominio. | |
| MX365614B (es) | Composiciones utiles para tratar trastornos relacionados con kit. | |
| MY176489A (en) | Novel tricyclic compounds as anticancer agents | |
| MX2020001756A (es) | Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos. | |
| PH12016500497A1 (en) | Compositions for the treatment of hypertension and/or fibrosis | |
| PH12016500495A1 (en) | Compositions for the treatment of hypertension and/or fibrosis | |
| PH12017500836A1 (en) | Transdermal formulations | |
| MX2014005510A (es) | Nuevas composiciones, produccion de las mismas y uso de las mismas para la produccion de poliamidas coladas. | |
| UA118670C2 (uk) | Способи та композиції для загоєння ран | |
| PH12017500348B1 (en) | Tetrahydroquinoline derivatives as bromodomain inhibitors | |
| UA117567C2 (uk) | Композиція, яка стимулює лактацію, на основі фосфатидилсерину | |
| MY182818A (en) | Compositions for the treatment of fibrosis and fibrosis-related conditions | |
| GEP20207145B (en) | Combination of trazodone and gabapentin for the treatmen | |
| MX2013008559A (es) | Derivados de leptina. | |
| AU2013903572A0 (en) | Compositions for the treatment of hypertension and/or fibrosis | |
| AU2013903573A0 (en) | Compositions for the treatment of hypertension and/or fibrosis | |
| AU2013903571A0 (en) | Compositions for the treatment of hypertension and/or fibrosis | |
| IN2013CH05770A (OSRAM) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2020 BY DENNEMEYER + CO Effective date: 20190829 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2021 BY DENNEMEYER + CO. Effective date: 20200907 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2022 BY DENNEMEYER + CO Effective date: 20210911 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2023 BY DENNEMEYER + CO. S.A.R.L. Effective date: 20220905 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2024 BY DENNEMEYER + CO. S.A.R.L. Effective date: 20230904 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2025 BY DENNEMEYER + CO. S.A.R.L. Effective date: 20240909 |